Target intelligence / Profile preview

Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma (PI3K-C2γ)

Target
PI3K-C2γ
Molecular classification
Enzyme, Kinase (specifically, lipid kinase), Phosphoinositide 3-kinase family (class II)
01

Overview

Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma (PI3K-C2γ) is a class II member of the PI3K family, which phosphorylates the 3-position of the inositol ring in phosphoinositides. The enzyme contains a C-terminal C2 domain—acting as a calcium-dependent phospholipid-binding motif—alongside a lipid kinase catalytic domain. PI3K-C2γ is involved in lipid signaling that regulates cellular processes such as intracellular protein trafficking, cell proliferation, and survival. Its specific biological functions remain incompletely characterized, but gene expression perturbations and pathway analyses suggest roles in cancer biology and potentially other diseases[4][8][2]. PI3K-C2γ differs from the more commonly studied PI3K isoforms (e.g., class I p110α, p110β, p110γ) in structure and regulatory mechanisms; unlike class I, it lacks a regulatory subunit and has unique N-terminal extensions[2]. No selective drugs or clinical biomarkers exist for this target at present.

Other names
PIK3C2GPI3K-C2-gammaPI3K-C2GAMMAphosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma
02

Mechanism of action

Lipid kinase inhibition (for hypothetical or research-stage modulators); general PI3K inhibition mechanism could apply if selective agents are developed

03

Biological functions

Signal transductionLipid signaling via generation of 3-phosphorylated phosphoinositidesRegulation of intracellular protein traffickingPotential roles in cell proliferation, survival, migration
04

Disease associations

Cancer (possible associations with cell proliferation and oncogenic transformation; gene perturbations reported in cancer datasets)Other (specific disease associations are under investigation)
05

Safety considerations

Unknown; PI3K class I inhibitors have notable toxicity profiles, but selective targeting of PI3K-C2γ is not a current clinical scenario

Beyond the preview

Go deeper on Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma (PI3K-C2γ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma (PI3K-C2γ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call